Ginkgo Bioworks announced on November 12, 2024, the successful completion of the first milestone in its partnership with Merck, focused on improving biologic manufacturing. This achievement triggered a research milestone payment of $9 million in cash to Ginkgo Bioworks.
The collaboration will now proceed to its second stage, which is dedicated to further enhancing the production process for biologics. This progression highlights the ongoing technical innovation and impactful work being conducted by Ginkgo's team in partnership with top pharmaceutical companies.
The milestone completion underscores Ginkgo's capabilities in strain engineering, high-throughput screening, and process development. These capabilities position Ginkgo as a valuable partner for pharmaceutical companies seeking to improve their biologic manufacturing processes.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.